S32826

S32826 is a potent autotaxin inhibitor, with an IC50 of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ) . S32826 inhibits LPA release from adipocytes[1].

Product Specifications

CAS Number

1096770-84-1

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/s32826.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC=C(C=C1)CP(O)(O)=O)CCCCCCCCCCCCC

Molecular Formula

C21H36NO4P

Molecular Weight

397.49

References & Citations

[1]Ferry G, et, al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther. 2008 Dec;327 (3) :809-19.|[2]Honjo M, et, al. Role of the Autotaxin-LPA Pathway in Dexamethasone-Induced Fibrotic Responses and Extracellular Matrix Production in Human Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci. 2018 Jan 1;59 (1) :21-30.|[3]Iyer P, et, al. Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS One. 2012;7 (8) :e42627.